Binh Nguyen, M.D., Ph.D., is vice president of oncology in global product development. Dr. Nguyen supports PPD’s overall oncology business, providing training and updates in the immuno-oncology field to internal personnel across all functions.
At PPD, Dr. Nguyen is a member of the oncology therapeutic area strategy team and the Immuno-oncology Center of Excellence. provides medical input on clinical development, study design and site selections to requests for proposals to maximize the probability of success of the studies, and works in collaboration with the clinical operations team to ensure efficient and timely execution of clinical studies. Dr. Nguyen supports PPD’s overall oncology business, providing training and updates in the immuno-oncology field to internal personnel across all functions.
Dr. Nguyen joined PPD in 2015 and has more than 20 years of regulatory and clinical development experiences in startup biotech and biopharma companies. He has held senior leadership roles where he was responsible for the clinical development of folate receptor and PSMA targeted anti-cancer and anti-inflammatory agents in conjunction with diagnostic imaging agents. As a chief medical officer in private industry, he focused on the clinical development of novel cancer agents licensed from the National Cancer Institute (NCI) and academic institutions. He was executive director of a global oncology platform team and pharmacogenomics program in the pharmaceutical industry, holding extensive interactions and negotiations with regulatory agencies worldwide that led to submissions and worldwide approvals of six oncology indications.
Dr. Nguyen holds a Bachelor of Science in chemistry and a Ph.D. in organic chemistry from Georgetown University in Washington, D.C., and a medical degree from the University of Maryland. After completing his internal medicine residency at Georgetown and his medical oncology fellowship at the NCI, he worked at the NCI Cancer Therapy Evaluation (CTEP), as well as the U.S. Food and Drug Administration’s (FDA) Division of Oncology Products prior to joining the biopharma industry.